Sign in
Taking people in PolandPhase 2

Mifamurtide compared with sorafenib-based treatment for high-risk osteosarcoma in children and young adults

Compares mifamurtide with standard sorafenib-containing treatment in young people with high-risk osteosarcoma.

Key facts

Who runs it
Instytut Matki I Dziecka
Where
Warsaw, PolandSee the 2 sites
Registry title
Clinical trial (study) comparing the efficacy and safety of mifamurtide versus standard treatment containing sorafenib in pediatric and young adult patients with high-risk osteosarcoma
Status
Recruiting
Phase
Phase 2
People taking part
40 people, planned
Started
23 Jun 2026
Expected to end
31 Jul 2033
Type of study
Interventional
Record updated
23 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children and young adults aged 5 to 30 years with high-risk osteosarcoma (bone cancer). The disease must be in complete remission or stable.

Age
5 to 30 years
Sex
All sexes can join.
Disease stage
Osteosarcoma confirmed by tissue examination, classed as high-risk. The disease is in complete remission or stable disease before randomization.
Earlier treatment
Surgery (major surgery at least 2 weeks before) and radiotherapy (at least 4 weeks before) must be finished. Recovery from side effects of earlier surgery or radiotherapy. No earlier treatment with mifamurtide.

Main reasons for not taking part

  • Another cancer diagnosed before joining
  • Blood clot or stroke in the last 6 months
  • Active or chronic hepatitis B or C needing antiviral treatment
  • Pregnant, planning pregnancy, or breastfeeding
  • Heart rhythm problems, heart failure symptoms, or uncontrolled high blood pressure

The registry criteria, word for word

Show all 26 criteriaShow less

Who can take part

  • Age ≥ 5 years and ≤ 30 years at the time of study enrollment
  • Recovery from adverse effects of prior surgery and/or radiotherapy
  • Consent to use effective contraception throughout the study period and for at least 1 year after discontinuation of study treatment in patients at pubertal and sexual maturity
  • Osteosarcoma confirmed by histopathological examination based on previously performed tests
  • Providing written, informed consent to participate in the study (including treatment with mifamurtide and sorafenib) in accordance with current legal regulations
  • Patient classified as high-risk
  • Life expectancy of at least 12 weeks from the date of signing the informed consent
  • Patient deemed fit to receive systemic treatment
  • Patient deemed able to swallow tablets
  • Disease in complete remission or stable disease according to WHO criteria prior to randomization
  • Completed surgery (major surgery ≥ 2 weeks) and radiotherapy (≥ 4 weeks) prior to IMP administration

Who cannot take part

  • Arterial or venous thrombotic or embolic events, such as stroke (including transient ischemic attacks), deep vein thrombosis, or pulmonary embolism, within the last 6 months before the first study drug administration
  • Any bleeding or hemorrhagic event ≥ CTCAE v5 grade 3 within 4 weeks before the first study drug administration
  • Diagnosis of other malignancies prior to study enrollment
  • Prior treatment with mifamurtide
  • Concomitant treatment with other drugs that may interact with mifamurtide or sorafenib or other cytotoxic agents
  • Persistent toxicity related to prior therapy precludes treatment with mifamurtide or sorafenib
  • Requirement or likely need for corticosteroids at doses >10 mg prednisolone (or equivalent) daily or other immunosuppressive medications
  • Failure to meet any of the inclusion criteria
  • Active hepatitis B or C infection or chronic hepatitis B or C infection requiring antiviral therapy
  • Hypersensitivity to the study drug or any of its components (including mifamurtide and sorafenib)
  • Other acute or persistent disorders, behaviors, or abnormal laboratory test results that may increase the risks associated with participation in this clinical trial or with the study drug, or that may affect the interpretation of the study results, or that, in the opinion of the investigator, disqualify the patient from participating in the study
  • Significant cardiac conduction abnormalities, including known familial long QT syndrome or a screening corrected QT interval (QTc) >480 ms
  • Symptoms of congestive heart failure or left ventricular ejection fraction <50%
  • Planning to become pregnant, being pregnant, or breastfeeding
  • Uncontrolled blood pressure (blood pressure values ​​not maintained within the recommended range (≥140/90 mmHg) despite treatment)

Where in Poland

  • Instytut Matki i DzieckaWarsaw, PolandTaking people
  • Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut BadawczyWarsaw, PolandTaking people

About the trial

What the trial wants to find out

Evaluation of clinical outcomes of treatment in the study patients, in particular event-free survival (EFS), and exploratory analysis of their relationship with molecular characteristics of the tumor

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A randomized phase II study comparing the safety and efficacy of mifamurtide and standard therapy containing sorafenib in pediatric and young adult patients with high-risk osteosarcoma
Plain-language title
Mifamurtide compared with sorafenib-based treatment for high-risk osteosarcoma in children and young adultsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
23 June 2026